Publications by authors named "Alexandra Savell"

Claim this Profile
P
Patterns of Treatment and Real-World Outcomes of Patients With Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT Study.
Geoffrey Liu, Shi Feng Nyaw, Tony S K Mok, Hubert Curcio, Alexis B Cortot, Alexandra Savell

Cancer Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings.
Jacqueline S Garcia, Yael Flamand, Livius Penter, Michael Keng, Benjamin K Tomlinson, Alexandra Savell

Blood· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.
Romanos Sklavenitis-Pistofidis, Michelle P Aranha, Robert A Redd, Joanna Baginska, Nicholas J Haradhvala, Alexandra Savell

Cancer Cell· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma.
Peter O'Gorman, Jacob P Laubach, Michael E O'Dwyer, Janusz Krawczyk, Andrew J Yee, Alexandra Savell

Am J Hematol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemia.
Yoshinobu Konishi, Romanos Sklavenitis-Pistofidis, Hong Yue, Federico Ferrari, Robert A Redd, Alexandra Savell

Cancer Cell· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation.
Livius Penter, Yi Zhang, Alexandra Savell, Teddy Huang, Nicoletta Cieri

Blood· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation.
Matthew S Davids, Haesook T Kim, Caitlin Costello, Alex F Herrera, Frederick L Locke, Alexandra Savell

Blood· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma.
Irene M Ghobrial, Chia-Jen Liu, Robert A Redd, Raymond P Perez, Rachid Baz, Alexandra Savell

Clin Cancer Res· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.
Matthew S Davids, Danielle M Brander, Haesook T Kim, Svitlana Tyekucheva, Jad Bsat, Alexandra Savell

Lancet Haematol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma.
Jacob P Laubach, Chia-Jen Liu, Noopur S Raje, Andrew J Yee, Philippe Armand, Alexandra Savell

Clin Cancer Res· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
Matthew S Davids, Haesook T Kim, Alyssa Nicotra, Alexandra Savell, Karen Francoeur

Lancet Haematol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients.
Romanos Sklavenitis-Pistofidis, Marzia Capelletti, Chia-Jen Liu, Mairead Reidy, Oksana Zavidij, Alexandra Savell

Blood· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ipilimumab for Patients with Relapse after Allogeneic Transplantation.
Matthew S Davids, Haesook T Kim, Pavan Bachireddy, Caitlin Costello, Rebecca Liguori, Alexandra Savell

N Engl J Med· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis